Prostate Cancer Prevention Act
Do you support it?
Want to know if it passes?
We'll email you when HR 5558 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 5558.
You're tracking HR 5558
We'll email you the moment it moves.
HR 5558 — Prostate Cancer Prevention Act
Last action — Referred to the Subcommittee on Health.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 117th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Prostate Cancer Prevention Act This bill reauthorizes through FY2026 a program within the Centers for Disease Control and Prevention that provides funding to states and local health departments for prostate cancer screening and related activities.
Bill Text
- Introduced Introduced in House Current html October 12, 2021
Sections of law this bill changes
1 section in 1 lawFrom the bill's own amending language, matched to the official United States Code (current through Public Law 119-124).
Public health service · 42 U.S.C. ch. 6A 1 section
-
§ 247b-5 Preventive health measures with respect to prostate cancer Amends
42 U.S.C. § 247b-5 — at 247b-5(l)(1)
The law today
(a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may make grants to States and local health departments for the purpose of enabling such States and departments to carry out programs that may include the following: (1) To identify factors that influence the attitudes or levels of awareness of men and health care practitioners regarding screening for prostate cancer. (2) To evaluate, in consultation with the Agency for Health Care Policy and Research and the National Institutes of Health, the effectiveness of screening strategies for prostate cancer. (3) To identify, in consultation with the Agency for Health Care Policy and Research, issues related to the quality of life for men after prostrate 1 cancer screening and followup. (4) To develop and disseminate public information and education programs for prostate cancer, including appropriate messages about the risks and benefits of prostate cancer screening for the general public, health care providers, policy makers and other appropriate individuals. (5) To improve surveillance for prostate cancer. (6) To address the needs of underserved and minority populations regarding prostate cancer. (7) Upon a determination by the Secretary, who shall take into consideration recommendations by the United States Preventive Services Task Force and shall seek input, where appropriate, from professional societies and other private and public entities, that there is sufficient consensus on the effectiveness of prostate cancer screening— (A) to screen men for prostate cancer as a preventive health measure; (B) to provide appropriate referrals for the medical treatment of men who have been screened under subparagraph (A) and to ensure, to the extent practicable, the provision of appropriate followup services and support services such as case management; (C) to establish mechanisms through which State and local health departments can monitor the quality of screening procedures for prostate cancer, including the interpretation of such procedures; and (D) to improve, in consultation with the Health Resources and Services Administration, the education, training, and skills of health practitioners (including appropriate allied health professionals) in the detection and control of prostate cancer. (8) To evaluate activities conducted under paragraphs (1) through (7) through appropriate surveillance or program monitoring activities. (b) Requirement of matching funds (1) In general The Secretary may not make a grant under subsection (a) unless the applicant involved agrees, with respect to the costs to be incurred by the applicant in carrying out the purpose described in such section, to make available non-Federal contributions (in cash or in kind under paragraph (2)) toward such costs in an amount equal to not less than $1 for each $3 of Federal funds provided in the grant. Such contributions may be made directly or through donations from public or private entities. (2) Determination of amount of non-Federal contribution (A) Non-Federal contributions required in paragraph (1) may be in cash or in kind, fairly evaluated, including equipment or services (and excluding indirect or overhead costs). Amounts provided by the Federal Government, or services assisted or subsidized to any significant extent by the Federal Government, may not be included in determining the amount of such non-Federal contributions. (B) In making a determination of the amount of non-Federal contributions for purposes of paragraph (1), the Secretary may include only non-Federal contributions in excess of the average amount of non-Federal contributions made by the applicant involved toward the purpose described in subsection (a) for the 2-year period preceding the fiscal year for which the applicant involved is applying to receive a grant under such subsection. (C) In making a determination of the amount of non-Federal contributions for purposes of paragraph (1), the Secr...
Compared against current U.S. Code AI-generated reading aid — verify against the official bill.
The bill reauthorizes funding for preventive health measures related to prostate cancer, adjusting the amount and time period of the funding.
-
42 U.S.C. 247b-5(l)(1)
$20,000,000 for fiscal year 1993, and such sums as may be necessary for each of the fiscal years 1994 through 2004→ $14,205,000 for each of fiscal years 2022 through 2026This change updates the funding amount and reauthorizes it for a new period specific to prostate cancer preventive health measures.
Action History
-
Referred to the Subcommittee on Health.
-
Introduced in House
-
Introduced in House
-
Referred to the House Committee on Energy and Commerce.
Sponsors
- Neal P. Dunn · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
- Dunn, Neal P. Republican
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 5558 do?
- Prostate Cancer Prevention Act This bill reauthorizes through FY2026 a program within the Centers for Disease Control and Prevention that provides funding to states and local health departments for prostate cancer screening and related activities.
- Who sponsors HR 5558?
- HR 5558 is sponsored by Dunn, Neal P. (Republican).
- What is the current status of HR 5558?
- This bill died with 117th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 5558?
- Track HR 5558 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 5558
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 5558
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →